Regeneron Pharmaceuticals, Inc. (REGN)
722.80
-0.87
(-0.12%)
USD |
NASDAQ |
Dec 04, 16:00
722.80
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 75.97B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -3.65% |
| Valuation | |
| PE Ratio | 17.30 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 5.590 |
| Price to Book Value | 2.454 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.88 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0874 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 59.69% |
Profile
| Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY. |
| URL | http://www.regeneron.com |
| Investor Relations URL | https://investor.regeneron.com/ |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 03, 2026 (est.) |
| Last Earnings Release | Oct. 28, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 20, 2025 |
Ratings
Profile
| Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY. |
| URL | http://www.regeneron.com |
| Investor Relations URL | https://investor.regeneron.com/ |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 03, 2026 (est.) |
| Last Earnings Release | Oct. 28, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 20, 2025 |